Kiniksa Pharmaceuticals (KNSA) Revenue & Revenue Breakdown
Kiniksa Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$270.26M
Latest Revenue (Q)
$108.63M
Main Segment (Y)
Product
Kiniksa Pharmaceuticals Revenue by Period
Kiniksa Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $270.26M | 22.74% |
| 2022-12-31 | $220.18M | 471.24% |
| 2021-12-31 | $38.54M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | - |
Kiniksa Pharmaceuticals generated $270.26M in revenue during NA 2023, up 22.74% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Kiniksa Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $108.63M | 36.03% |
| 2024-03-31 | $79.86M | -4.24% |
| 2023-12-31 | $83.39M | 24.38% |
| 2023-09-30 | $67.05M | -6.19% |
| 2023-06-30 | $71.47M | 47.84% |
| 2023-03-31 | $48.34M | -21.88% |
| 2022-12-31 | $61.88M | -37.58% |
| 2022-09-30 | $99.14M | 267.55% |
| 2022-06-30 | $26.97M | -16.21% |
| 2022-03-31 | $32.19M | 71.72% |
| 2021-12-31 | $18.75M | 54.98% |
| 2021-09-30 | $12.10M | 57.00% |
| 2021-06-30 | $7.70M | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Kiniksa Pharmaceuticals generated $108.63M in revenue during Q2 2024, up 36.03% compared to the previous quarter, and up 224.70% compared to the same period a year ago.
Kiniksa Pharmaceuticals Revenue Breakdown
Kiniksa Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 |
|---|---|---|
| Product | $233.18M | $122.52M |
| Collaboration | $37.08M | $97.66M |
Kiniksa Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (86.28%), and Collaboration (13.72%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
|---|---|---|---|---|---|---|---|---|
| Collaboration | $5.24M | $14.42M | $16.98M | $5.69M | $21.95M | - | - | - |
| Product | $103.39M | $136.02M | $54.49M | $42.66M | $39.94M | $33.42M | $26.97M | $22.19M |
Kiniksa Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (95.18%), and Collaboration (4.82%).
Kiniksa Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals | $270.26M | $108.63M |
| CHRS | Coherus BioSciences | $257.24M | $64.98M |
| ACLX | Arcellx | $110.32M | $27.38M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| BOLT | Bolt Biotherapeutics | $7.88M | $1.27M |
| KRON | Kronos Bio | $6.29M | $2.69M |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| PHAT | Phathom Pharmaceuticals | $682.00K | $1.91M |
| KRTX | Karuna Therapeutics | $654.00K | - |
| CGEM | Cullinan Oncology | - | - |
| GPCR | Structure Therapeutics | - | - |
| GRCL | Gracell Bio | - | - |
| NUVL | Nuvalent | - | - |
| COGT | Cogent Biosciences | - | - |
| GOSS | Gossamer Bio | - | $95.84M |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| CERE | Cerevel Therapeutics | - | - |
| REPL | Replimune Group | - | - |
| KURA | Kura Oncology | - | - |
| NLTX | Neurogene | - | - |
| VTYX | Ventyx Biosciences | - | - |
| LRMR | Larimar Therapeutics | - | - |
| NVCT | Nuvectis Pharma | - | - |
KNSA Revenue FAQ
What is Kiniksa Pharmaceuticals’s yearly revenue?
Kiniksa Pharmaceuticals's yearly revenue for 2023 was $270.26M, representing an increase of 22.74% compared to 2022. The company's yearly revenue for 2022 was $220.18M, representing an increase of 471.24% compared to 2021. KNSA's yearly revenue for 2021 was $38.54M, representing an increase of 100.00% compared to 2020.
What is Kiniksa Pharmaceuticals’s quarterly revenue?
Kiniksa Pharmaceuticals's quarterly revenue for Q2 2024 was $108.63M, a 36.03% increase from the previous quarter (Q1 2024), and a 51.99% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $79.86M, a -4.24% decrease from the previous quarter (Q4 2023), and a 65.18% increase year-over-year (Q1 2023). KNSA's quarterly revenue for Q4 2023 was $83.4M, a 24.38% increase from the previous quarter (Q3 2023), and a 34.76% increase year-over-year (Q4 2022).
What is Kiniksa Pharmaceuticals’s revenue growth rate?
Kiniksa Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 601.17%, and for the last 5 years (2019-2023) was 0%.
What are Kiniksa Pharmaceuticals’s revenue streams?
Kiniksa Pharmaceuticals's revenue streams in c 23 are Product, and Collaboration. Product generated $233.18M in revenue, accounting 86.28% of the company's total revenue, up 90.31% year-over-year. Collaboration generated $37.08M in revenue, accounting 13.72% of the company's total revenue, down -62.03% year-over-year.
What is Kiniksa Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Kiniksa Pharmaceuticals was Product. This segment made a revenue of $233.18M, representing 86.28% of the company's total revenue.